Latest Regulatory Filings News

H&S Group has exercised performance options to increase its stake in Nuchev Limited to 48.62%, injecting $1.9 million and enhancing Nuchev’s financial flexibility for growth.

BlinkLab is advancing its FDA 510(k) clinical trials for autism and ADHD diagnostics, completing its U.S. autism pilot phase and expanding European ADHD recruitment. A recent $7.66 million capital raise supports these efforts as the company targets regulatory approvals in 2026.

Epx Limited reports sustained operational improvement with four consecutive quarters of positive cash inflows and a 26% increase in customer receipts for the June 2025 quarter.

D3 Energy has achieved a significant milestone with its maiden certified methane and helium reserves at ER315 in South Africa, enabling an early submission of its Production Right application. The reserves cover a small portion of the acreage but signal substantial upside potential.

Yowie Group Limited has explained the delayed filing of director interest notices following a contested board change, committing to stronger governance measures to prevent future lapses.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.

Polymetals Resources has updated its June 2025 quarterly cash flow report, confirming nearly two quarters of funding and ongoing revenue from concentrate sales. The company’s financing position remains stable amid planned equity issuance.

Prodigy Gold NL has lodged a replacement Appendix 3Y to amend the reported securities held by Managing Director Mark Edwards following his participation in the company’s recent Entitlement Offer.

Austal Limited has acknowledged a delayed filing of a director's interest notice due to an administrative oversight, prompting ASX scrutiny and a commitment to tighten compliance processes.

Cleo Diagnostics reports steady progress in its ovarian cancer diagnostic test development, with clinical trial recruitment on track and strategic access to major biobanks enhancing its regulatory pathway.

29Metals Limited's June Quarter 2025 report highlights steady production at Golden Grove with revised capital guidance, while Capricorn Copper remains suspended but progresses on key environmental and regulatory fronts.